1. A phase I study of the GM-CSF antagonist E21R

   • Ian N. Olver
   • Tim Hercus
   • Peter Wigley

   Original Article Pages: 171 - 178

2. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate

   • Khalid Matin
   • Merrill J. Egorin
   • Donald L. Trump

   Original Article Pages: 179 - 185

3. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide

   • Qi Ding
   • Philip Kestell
   • Lai-Ming Ching

   Original Article Pages: 186 - 192

4. Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM

   • Takeshi Takahashi
   • Makiko Shimizu
   • Shiro Akinaga

   Original Article Pages: 193 - 201

5. In vitro and in vivo effects of repifermin (keratinocyte growth factor-2, KGF-2) on human carcinoma cells

   • Ralph Alderson
   • Shiva Gohari-Fritsch
   • Kevin Connolly

   Original Article Pages: 202 - 212

6. Stimulation of TNF-α production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) – a novel immunomodulator with potential application in tumour immunotherapy

   • Witold Lasek
   • Tomasz Świtaj
   • Zygmunt Kazimierczuk

   Original Article Pages: 213 - 222

7. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

   • Lynn Feun
   • Manuel Modiano
   • Susan MacDonald

   Original Article Pages: 223 - 229

8. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients

   • T. Ishibashi
   • Y. Yano
   • T. Oguma

   Original Article Pages: 230 - 236

9. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies

   • Apostolia-Maria Tsimberidou
   • Deborah Thomas
   • Francis Giles

   Original Article Pages: 237 - 242

10. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support

    • Meiyu Shen
    • Russell J. Schilder
    • James M. Gallo

    Original Article Pages: 243 - 250

11. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin

    • Milly E. de Jonge
    • Ron A. Mathôt
    • Sjoerd Rodenhuis

    Short Communication Pages: 251 - 255